ArticleJournal of clinical medicine2022

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn's Disease: Results from an Early Access Program in Brazil.

Julio Maria Fonseca Chebli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.